ZNTL - Zentalis Pharmaceuticals Inc Stock Price, Fair Value and News

11.50USD+0.08 (+0.70%)Delayed as of 30 Apr 2024, 11:06 am ET

Market Summary

USD11.50+0.08

Delayedas of 30 Apr 2024, 11:06 am

0.70%

ZNTL Stock Price

View Fullscreen

ZNTL RSI Chart

ZNTL Valuation

Market Cap

810.4M

Price/Earnings (Trailing)

-2.77

EV/EBITDA

-2.84

Price/Free Cashflow

-3.89

MarketCap/EBT

-2.93

ZNTL Price/Sales (Trailing)

ZNTL Profitability

Return on Equity

-66.82%

Return on Assets

-52.96%

Free Cashflow Yield

-25.72%

ZNTL Fundamentals

ZNTL Earnings

Earnings (TTM)

-292.2M

Earnings Growth (Yr)

-10.82%

Earnings Growth (Qtr)

-9.71%

Breaking Down ZNTL Revenue

52 Week Range

11.0431.46

(Low)(High)

Last 7 days

-12.1%

Last 30 days

-27.5%

Last 90 days

-5.6%

Trailing 12 Months

-48.2%

How does ZNTL drawdown profile look like?

ZNTL Financial Health

Current Ratio

7.16

ZNTL Investor Care

Shares Dilution (1Y)

24.00%

Diluted EPS (TTM)

-4.51

Tracking the Latest Insider Buys and Sells of Zentalis Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 12, 2024	epperly melissa b,	sold	-29,435	11.44	-2,573	chief financial officer
Feb 12, 2024	gallagher cam	sold	-13,419	11.44	-1,173	president
Feb 02, 2024	paul andrea	sold	-38,197	11.54	-3,310	chief legal officer
Feb 02, 2024	epperly melissa b,	sold	-100,040	11.54	-8,669	chief financial officer
Feb 02, 2024	gallagher cam	sold	-133,310	11.54	-11,552	president
Feb 02, 2024	lackner mark	sold	-18,290	11.54	-1,585	chief scientific officer
Feb 01, 2024	hausman diana	acquired	-	-	337,500	chief medical officer
Feb 01, 2024	blackwell kimberly	sold (taxes)	-241,457	11.69	-20,655	chief executive officer
Feb 01, 2024	epperly melissa b,	acquired	-	-	75,000	chief financial officer
Feb 01, 2024	lackner mark	acquired	-	-	141,000	chief scientific officer

Which funds bought or sold ZNTL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Zurcher Kantonalbank (Zurich Cantonalbank)	added	100	127,834	246,140	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-0.09	172,949	4,568,510	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	sold off	-100	-470,000	-	-%
Apr 25, 2024	Lindbrook Capital, LLC	new	-	1,875	1,875	-%
Apr 23, 2024	Values First Advisors, Inc.	added	47.84	391,774	1,120,000	0.66%
Apr 23, 2024	AMALGAMATED BANK	reduced	-76.05	-95,000	31,000	-%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	new	-	190,901	190,901	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	-150,747	465,135	-%
Apr 19, 2024	Cutler Group LLC / CA	reduced	-33.33	-4,000	9,000	-%
Apr 16, 2024	OneAscent Financial Services LLC	added	10.68	24,000	180,000	0.02%

Are Funds Buying or Selling ZNTL?

Are funds buying ZNTL calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ZNTL

No. of Funds

Unveiling Zentalis Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	citadel advisors llc	5.1%	6	SC 13G/A
Feb 13, 2024	avidity partners management lp	0%	0	SC 13G/A
Feb 13, 2024	vanguard group inc	7.56%	5,350,458	SC 13G/A
Feb 09, 2024	wellington management group llp	0.10%	68,791	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 09, 2024	capital international investors	4.0%	2,819,664	SC 13G/A
Jan 29, 2024	blackrock inc.	6.6%	4,684,975	SC 13G/A
Jan 25, 2024	state street corp	6.24%	4,417,056	SC 13G/A
Dec 11, 2023	eventide asset management, llc	16.34%	11,559,975	SC 13G/A
Nov 17, 2023	citadel advisors llc	5.1%	6	SC 13G

Recent SEC filings of Zentalis Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Apr 29, 2024	ARS	ARS
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	DEFA14A	DEFA14A
Apr 11, 2024	3	Insider Trading
Apr 11, 2024	8-K	Current Report
Apr 09, 2024	8-K	Current Report
Feb 29, 2024	S-3ASR	S-3ASR
Feb 29, 2024	S-8	Employee Benefits Plan
Feb 27, 2024	10-K	Annual Report
Feb 27, 2024	8-K	Current Report

Peers (Alternatives to Zentalis Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	42.6B	6.8B	4.75%	-16.01%	-9.05	6.23	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.6B	1.8B	-1.40%	-26.02%	-42.16	10.15	76.23%	61.08%
BMRN	15.4B	2.5B	-5.97%	-14.48%	74.78	6.22	13.74%	186.89%
INCY	11.8B	3.7B	-7.74%	-29.36%	19.75	3.19	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-18.63%	-42.67%	-10.91	14.55	425.83%	18.94%
BBIO	4.5B	-	-17.63%	75.41%	-6.86	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-7.66%	3.02%	-14.59	12.9	440.80%	-27.84%
ARWR	2.9B	240.7M	-19.13%	-34.68%	-9.65	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.52%	-19.83%	-45.97	3.88	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.45%	-4.33%	25.14	4.51	85.90%	-14.05%
NVAX	600.4M	983.7M	-10.25%	-44.07%	-1.1	0.61	-50.36%	17.16%
CRBP	374.0M	881.7K	-9.17%	305.92%	-8.38	466.16	-77.61%	-5.33%
INO	268.8M	4.9M	-17.15%	24.46%	-1.99	55.23	-54.97%	51.71%
IBIO	5.8M	2.1M	-59.11%	53.70%	-0.21	2.14	-13.45%	66.37%

Zentalis Pharmaceuticals Inc News

Latest updates

Zentalis Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																		(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2018Q4
Assets	-5.8%	552	586	621	489	539	529	568	406	455	435	284	328	366	393	257	88.00	87.00	41.00
Current Assets	-6.0%	497	528	564	410	452	434	468	301	351	378	259	306	345	373	238	66.00	69.00	27.00
Cash Equivalents	-74.7%	28.00	111	267	36.00	43.00	43.00	55.00	31.00	60.00	41.00	49.00	29.00	56.00	93.00	96.00	64.00	67.00	25.00
Net PPE	-9.0%	6.00	6.00	7.00	7.00	8.00	8.00	8.00	8.00	8.00	5.00	2.00	2.00	1.00	0.00	0.00	1.00	1.00	0.00
Goodwill	0%	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00
Liabilities	10.1%	114	104	98.00	104	105	100	95.00	90.00	90.00	41.00	36.00	36.00	32.00	27.00	19.00	21.00	19.00	9.00
Current Liabilities	17.7%	69.00	59.00	52.00	56.00	57.00	54.00	49.00	43.00	44.00	39.00	34.00	33.00	29.00	24.00	16.00	17.00	15.00	6.00
Shareholder's Equity	-9.2%	437	482	523	386	434	429	473	316	364	394	248	293	333	366	238	-	-	32.00
Retained Earnings	-7.4%	-888	-827	-772	-659	-596	-541	-486	-418	-359	-309	-305	-250	-200	-160	-125	-99.12	-82.99	-37.33
Additional Paid-In Capital	1.1%	1,324	1,310	1,296	1,046	1,031	972	961	735	724	703	529	519	509	502	339	-	-	-
Shares Outstanding	0.2%	71.00	71.00	71.00	59.00	59.00	51.00	51.00	45.00	43.00	42.00	41.00	40.00	-	-	-	-	-	-
Minority Interest	-17.1%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	24.00	24.00	25.00	-	-	7.00	7.00	-
Float	-	-	-	1,560	-	-	-	1,300	-	-	-	1,760	-	-	-	1,150	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-5.0%	-40,599	-38,665	-79,275	-49,283	-37,329	-33,199	-43,027	-50,196	-37,021	-33,490	-46,113	-37,469	-27,357	-20,564	-22,033	-16,871	-13,191	-9,988	-6,958	-9,006	-
Share Based Compensation	0.1%	13,880	13,867	13,342	13,733	9,612	10,317	16,764	10,147	8,471	7,656	9,919	9,691	7,887	7,249	7,681	329	212	155	121	129	-
Cashflow From Investing	64.2%	-42,060	-117,451	72,932	42,121	-11,894	20,018	-142,100	19,796	43,267	-141,443	66,603	13,458	-9,650	-137,890	-137,261	-31.00	-36.00	-107	-168	-41.00	-
Cashflow From Financing	-100.0%	-	309	236,621	373	49,741	589	209,455	1,258	12,267	166,570	-316	-	-594	155,899	191,660	13,474	-53.00	81,883	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ZNTL Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Operating Expenses
Research and development	$ 189,590	$ 172,734	$ 175,601
Zentera in-process research and development	45,568	0	0
General and administrative	64,351	54,553	40,941
Total operating expenses	299,509	227,287	216,542
Loss from operations	(299,509)	(227,287)	(216,542)
Other Income (Expense)
Investment and other income, net	22,617	5,987	401
Gain on deconsolidation of Zentera	0	0	51,582
Net loss before income taxes	(276,892)	(221,300)	(164,559)
Income tax benefit	(601)	(469)	(297)
Loss on equity method investment	16,014	16,282	1,831
Net loss	(292,305)	(237,113)	(166,093)
Net loss attributable to noncontrolling interests	(114)	(307)	(7,368)
Net loss attributable to Zentalis	$ (292,191)	$ (236,806)	$ (158,725)
Net loss per common share outstanding, basic (in dollars per share)	$ (4.47)	$ (4.48)	$ (3.72)
Net loss per common share outstanding, diluted (in dollars per share)	$ (4.47)	$ (4.48)	$ (3.72)
Common shares used in computing net loss per share, basic (in shares)	65,409	52,857	42,688
Common shares used in computing net loss per share, diluted (in shares)	65,409	52,857	42,688

ZNTL Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 28,038	$ 43,069
Marketable securities, available for sale	454,881	394,302
Prepaid expenses and other current assets	13,799	14,562
Total current assets	496,718	451,933
Property and equipment, net	5,819	7,705
Operating lease right-of-use assets	35,916	42,373
Prepaid expenses and other assets	6,818	9,723
Goodwill	3,736	3,736
Investment in Zentera Therapeutics	0	21,213
Restricted cash	2,681	2,627
Total assets	551,688	539,310
Current liabilities
Accounts payable	14,926	11,247
Accrued expenses	54,441	45,400
Total current liabilities	69,367	56,647
Deferred tax liability	0	853
Long-term lease liability	43,150	45,166
Other long-term liabilities	1,780	2,620
Total liabilities	114,297	105,286
Commitments and contingencies (see Note 10)
EQUITY
Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding at December 31, 2023 and 2022	0	0
Common stock, $0.001 par value; 250,000,000 shares authorized; 70,765,554 and 59,280,247 shares issued and outstanding at December 31, 2023 and 2022, respectively	70	59
Additional paid-in capital	1,323,576	1,031,462
Accumulated other comprehensive income/(loss)	2,194	(1,353)
Accumulated deficit	(888,556)	(596,365)
Total stockholders' equity	437,284	433,803
Noncontrolling interests	107	221
Total equity	437,391	434,024
Total liabilities and stockholders' equity	$ 551,688	$ 539,310

About Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics: and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

CEO	Dr. Kimberly Lynn Blackwell M.D.
WEBSITE	https://zentalis.com
INDUSTRY	Biotechnology
EMPLOYEES	156

Zentalis Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Zentalis Pharmaceuticals Inc? What does ZNTL stand for in stocks?

ZNTL is the stock ticker symbol of Zentalis Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Zentalis Pharmaceuticals Inc (ZNTL)?

As of Mon Apr 29 2024, market cap of Zentalis Pharmaceuticals Inc is 810.37 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ZNTL stock?

You can check ZNTL's fair value in chart for subscribers.

What is the fair value of ZNTL stock?

You can check ZNTL's fair value in chart for subscribers. The fair value of Zentalis Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Zentalis Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ZNTL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Zentalis Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether ZNTL is over valued or under valued. Whether Zentalis Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Zentalis Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ZNTL.